More Data Challenges For Boston Sci’s Watchman In Lead-Up To Latest Panel
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific’s Watchman left-atrial appendage occluder for reducing stroke risk in patients at risk for thromboembolism missed both co-primary efficacy endpoints in the latest follow-up data from the PREVAIL study, but at least one analyst believes it still has a good chance of earning another endorsement from an FDA advisory panel in October. And metaanalysis data offered more support.